Entyvio Seen as Superior to Humira in Treating Active UC, Phase 3 Trial Shows

Entyvio Seen as Superior to Humira in Treating Active UC, Phase 3 Trial Shows
One year of treatment with Entyvio (vedolizumab) was found to be superior to Humira (adalimumab) in achieving disease remission in people with ulcerative colitis (UC), a common form of inflammatory bowel disease (IBD), Takeda announced.  A head-to-head comparison of these anti-inflammatory therapies was made in the VARSITY trial (NCT02497469), a Phase 3b, randomized, double-blind, multi-center study sponsored by the company.  Trial results were published in The New England Journal of Medicine in the study, “Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis”. AbbVie's Humira is an anti-inflammatory medication used to treat UC. Adalimumab is an anti-TNF therapy that works by blocking the inflammatory signaling molecule TNF (tumor necrosis factor). However, some patients either do not respond well to or cannot tolerate this therapy, or other standard corticosteroid therapies. Entyvio, by Takeda, is an alternative anti-inflammatory medicine that works by a different mechanism — it prevents inflammatory cells from getting into the intestines.  This study directly compared the efficacy and safety of Entyvio to Humira in 769 people with moderately or severely active UC, all of whom failed to adequately respond to a previous treatment.  Patients were divided into two groups. The Entyvio group, which had 383 people, were given 300 mg of the therapy intravenously (IV) on day one, and again at weeks two and six, followed by infusions every eight weeks until week 46.  Humira was given to 386 patients by subcutaneous (SC) injection at 160 mg on day one and 80 mg at week two, followed by 40 mg every two weeks until week 50.  As these medicines were administered differently (IV versus SC), patients in the Entyvio group a
Subscribe or to access all post and page content.